In a long-awaited finding, a team of Chinese and US scientists has determined the high-resolution atomic structure of a ... that block the virus from binding to CCR5 or otherwise render the ...

The crystal structure reveals exactly where that binding site is located and how the drug orients itself to exert its activity—blocking HIV’s gp120 surface glycoprotein from binding CCR5.

CCL5/RANTES is a chemokine that binds to the chemokine receptor CCR5. CCR5 is expressed on immune cells such as T-lymphocytes, macrophages, and NK cells. CCL5/RANTES acts like a magnet for these ...

Am J Health Syst Pharm. 2009;66(8):715-726. Mechanism of action of maraviroc. Before fusion of the HIV viral envelope and host cell membrane can occur, an HIV glycoprotein complex consisting of ...

The crystallographic determination of the CCR5 receptor ... in the HIV binding region—differences that will be of interest to HIV drug developers. “Knowing the CXCR4 structure and now the ...

available for HIV binding. The study also revealed aspects of the CCR5/drug complex distinct from the structure of the other co-receptor: CXCR4 bound to its inhibitor. The CCR5/drug complex binds ...

Human immunodeficiency virus (HIV) infection is a viral infection that causes acquired immunodeficiency syndrome (AIDS) by gradually destroying certain leukocytes. When HIV enters the human body ...

two drugs that slow down the spread of the HIV virus by targeting the CCR5 co-receptor of the chemokine CCL5, also prevents migration and spread of basal breast cancer cells, the researchers found.

Serum from patients receiving maraviroc prevented CCR5 internalization by CCL5 and blocked T-cell chemotaxis in vitro, providing evidence of antichemotactic activity. In this study, inhibition of ...

SHANGHAI, CHINA, AND LA JOLLA, CA – In a long-awaited finding, a team of Chinese and US scientists has determined the high-resolution atomic structure ... virus from binding to CCR5 or otherwise ...